Scott Ward

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Broadfin Healthcare Fund LP provides healthcare funding services. Broadfin Advisors LLC is the general partner of the company. The company is headquartered in New York.

Broadfin Healthcare Offshore Fund Ltd. invests and trades securities and other financial instruments. The company is headquartered in George Town, Cayman Islands.

CNS Therapeutics, Inc. develops and manufactures drug delivery products. The company was founded in 2007 and is headquartered in St. Paul, MN.

SpineThera, Inc. engages in the designs and development of injectable drugs to meet the requirements for administration in and near the spine. Its product include SX600, an investigational drug. The company was founded by Jeffrey Missling and is headquartered in Plymouth, MN.

Advanced Respiratory, Inc. manufactures and distributes non-invasive airway clearance products and systems. The company is headquartered in St. Paul, MN.

Broadfin Capital LLC (Broadfin) is an independent hedge fund manager headquartered in New York City. The firm was founded by Kevin Kotler in 2005. Through the funds they advise, the firm may provide investment management services to individuals, investment companies, pooled investment vehicles, pension and profit sharing plans, trusts, estates, governmental plans, endowments, foundations, charitable organizations, corporations, insurance companies, limited partnerships, commingled investment trusts, and other entities.

Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO.